Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

11.60 +0.31 (+2.70%)
Streaming Delayed Price Updated: 12:55 PM EDT, Sep 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Upgrades 
Via Benzinga
7 Analysts Have This to Say About Intellia Therapeutics
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings: 
Via Benzinga
Intellia Therapeutics Shares Are Gaining After Positive Data From Second CRISPR Candidate
 
Via Benzinga
Expert Ratings for Intellia Therapeutics
Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
The Top 5 Stocks Cathie Wood Is Buying This Week
Cathie Wood announced that she would step down as portfolio manager for PRNT and IZRL. That hasn't stopped her from making her usual buys. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022
Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago... 
Via Benzinga
5 Top Stocks Cathie Wood Is Buying Right Now
Cathie Wood's ARKK is down over 50% YTD, although the fund manager is still continuing her purchases of high conviction companies. 
Via InvestorPlace
Expert Ratings for Intellia Therapeutics
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings: 
Via Benzinga
SVB Leerink Maintains Outperform Rating for Intellia Therapeutics: Here's What You Need To Know
SVB Leerink has decided to maintain its Outperform rating of Intellia Therapeutics (NASDAQ:NTLA) and raise its price target from $152.00 to $158.00. Shares of Intellia Therapeutics are trading down... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Intellia Therapeutics
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings: 
Via Benzinga
This Analyst Cuts PT On Adobe, Plus Barclays Predicts $240 For FedEx
Wells Fargo lowered the price target for Adobe Inc. (NASDAQ: ADBE) from $425 to $310. Adobe shares fell 1.2% to $296.04 in pre-market trading. 
Via Benzinga
Why Is Applied Optoelectronics (AAOI) Stock Up 35% Today?
Applied Optoelectronics (AAOI) stock is climbing higher on Friday after the company revealed a $150 million asset sale and new brand launch. 
Via InvestorPlace
Why Is Esports Entertainment (GMBL) Stock Down 45% Today?
Esports Entertainment (GMBL) stock is falling hard on Friday after the company revealed the pricing of a public stock offering. 
Via InvestorPlace
What Is Going on With Intellia Therapeutics (NTLA) Stock Today?
Intellia Therapeutics (NTLA) stock is on the move Friday after releasing positive clinical trial data for two of its drugs. 
Via InvestorPlace
Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies
 
Via Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Intellia Gets FDA Orphan Drug Status For Hereditary Angioedema Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ: NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE).... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
Upgrades 
Via Benzinga
Where Intellia Therapeutics Stands With Analysts
Over the past 3 months, 5 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Why XPeng Shares Traded Lower By Around 11%; Here Are 77 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Macy's, Palo Alto Networks And Other Big Gainers From Tuesday
U.S. stocks closed mostly lower with the Dow Jones dropping more than 150 points on Tuesday. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up. 
Via InvestorPlace
7 Stock Price Predictions That Are Actually Worth Listening To
Investors may take advantage of analyst stock price predictions beyond the recent share price to discover promising investments. 
Via InvestorPlace
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion
Shares of Pfizer's rumored takeover target have rocketed for two days running. 
Via Investor's Business Daily
Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug
The company will compete with Pfizer, which already has an approved drug. 
Via Investor's Business Daily
Clorox, Crocs And Some Other Big Stocks Moving Lower On Thursday
  AMTD Digital Inc. (NYSE: HKD) dipped 43.6% to $620.00 on possible profit taking after the stock surged over the last few trading days. 
Via Benzinga
Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned
Intellia is backing off the higher dose of a gene-editing drug in cardiomyopathy patients. 
Via Investor's Business Daily
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.